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Summary
Our understanding of Ewing’s sarcoma development mediated by the EWS/FLI fusion protein has been limited by a lack of
knowledge regarding the tumor cell of origin. To circumvent this, we analyzed the function of EWS/FLI in Ewing’s sarcoma
itself. By combining retroviral-mediated RNA interferencewith reexpression studies, we show that ongoing EWS/FLI expres-
sion is required for the tumorigenic phenotype of Ewing’s sarcoma. We used this system to define the full complement of
EWS/FLI-regulated genes in Ewing’s sarcoma. Functional analysis revealed that NKX2.2 is an EWS/FLI-regulated gene
that is necessary for oncogenic transformation in this tumor. Thus, we developed a highly validated transcriptional profile
for the EWS/FLI fusion protein and identified a critical target gene in Ewing’s sarcoma development.Introduction
Ewing’s sarcoma is a highly aggressive bone-associated tumor
of children and young adults. Most cases of Ewing’s sarcoma
have a recurrent chromosomal translocation, t(11;22)(q24;q12),
that encodes the EWS/FLI fusion protein (Delattre et al., 1992).
The FLI portion contains an ETS family DNA binding domain,
while the EWS portion functions as a strong transcriptional
activation domain (Delattre et al., 1992; Lessnick et al., 1995;
May et al., 1993a, 1993b). EWS/FLI is thus an aberrant tran-
scription factor that dysregulates target genes involved in tumor
development.
One difficulty in understanding EWS/FLI function has been the
lack of an appropriate model system in which to study the fu-
sion. Because the cell of origin of Ewing’s sarcoma is unknown,
most studies have relied on heterologous cell types with uncer-
tain relevance to the human disease. For example, when intro-
duced into NIH3T3 mouse fibroblasts, EWS/FLI causes onco-
genic transformation (May et al., 1993a). When introduced into
other cell types, such as primary human or mouse fibroblasts,
EWS/FLI causes growth arrest or cell death (Deneen and Denny,
2001; Lessnick et al., 2002). Cellular background is thereforeCANCER CELL 9, 405–416, MAY 2006 ª2006 ELSEVIER INC. DOI 10.101important in determining the phenotypic response to EWS/FLI
expression. This suggests that there may be different gene ex-
pression changes associated with EWS/FLI expression related
to the cell type used.
A number of potential EWS/FLI target genes have been iden-
tified in heterologous cell systems (e.g., Braun et al., 1995; De-
neen et al., 2003; Lessnick et al., 2002; May et al., 1997; Thomp-
son et al., 1996). However, it has been difficult to define the role
of these target genes in Ewing’s sarcoma development. Much of
this difficulty has been due to the relatively subtle oncogenic
effects of many of these targets in NIH3T3 cells, such as
MFNG, EAT2, and UPP (Deneen et al., 2003; May et al., 1997;
Thompson et al., 1996). Indeed, the subtle oncogenic effects
of these targets have suggested a model for Ewing’s sarcoma
development whereby EWS/FLI upregulates multiple weak on-
cogenes, and it is only through the additive effects of these tar-
gets that cancer development occurs. This model predicts that
loss of any one of these targets in Ewing’s sarcoma cells would
have only a minimal effect on oncogenic transformation.
Rather than studying EWS/FLI in a heterologous cell type, we
developed a system to analyze the effects of EWS/FLI in Ewing’s
sarcoma itself. We used this system to determine the genes thatS I G N I F I C A N C E
Ewing’s sarcoma is an important model for pediatric cancer development because it is virtually defined by a single oncogenic event,
the EWS/FLI fusion. EWS/FLI is an aberrant transcription factor, but only a few targets have been identified, and these have mostly come
from studies in heterologous cell types. We describe a generalizable approach to study the fusion in Ewing’s sarcoma itself and use this
system to comprehensively define the transcriptional profile of EWS/FLI. We identified a critical target gene that has not been previously
implicated in cancer development. The approach we describe has clear advantages over prior model systems and can be used to
study other oncogenic transcription factors in their ‘‘native’’ context as well.6/j.ccr.2006.04.004 405
A R T I C L Eare dysregulated by EWS/FLI (both directly and indirectly).
Functional studies revealed that one of these, NKX2.2, is abso-
lutely required for oncogenic transformation in Ewing’s sarcoma
cells but is not sufficient to mediate oncogenesis by itself. This
supports a model in which EWS/FLI upregulates multiple target
genes, and each gene contributes a nonredundant function to-
ward cancer development. This has diagnostic and therapeutic
implications for this important pediatric cancer.
Results
EWS/FLI is required for Ewing’s sarcoma
oncogenic transformation
To analyze the effects of EWS/FLI in its native cellular back-
ground, we used retroviral-mediated RNAi to ‘‘knock down’’ en-
dogenous fusion expression. We designed a construct (desig-
nated EF-2-RNAi) directed against the 30 untranslated region
(30 UTR) of EWS/FLI (Figure 1A). Wild-type FLI is not expressed
in Ewing’s sarcoma cells (Figure 1B), and so EF-2-RNAi targets
only EWS/FLI. Retroviruses targeting luciferase or ERG, neither
of which are expressed in these cells (data not shown), served
as negative controls and were designated luc-RNAi and ERG-
RNAi, respectively. Following infection and puromycin selection
of A673 Ewing’s sarcoma cells, we found that EF-2-RNAi effec-
tively knocked down both EWS/FLI transcript (Figure 1C) and
protein levels (Figure 1D).
To investigate the function of EWS/FLI in Ewing’s sarcoma,
the phenotype of A673 Ewing’s sarcoma cells harboring the
EF-2-RNAi construct was assessed. These cells maintained
a growth rate that was identical to cells infected with control ret-
roviruses (Figure 2A). The level of EWS/FLI expression in the
knockdown cells was the same at the beginning and the end
of the growth curve time course (data not shown). Thus, the nor-
mal growth of A673 cells harboring the EF-2-RNAi construct was
not due to silencing or loss of the construct. Over a prolonged
period of time (weeks to months), we detect diminished activity
of the EF-2-RNAi construct, suggesting either a subtle growth
effect that is not detected in the assays performed above, or
nonspecific silencing of the RNAi construct occurs (data not
shown).
To determine if oncogenic transformation is dependent on
EWS/FLI, we infected A673 cells or 293EBNA (transformed hu-
man embryonic kidney cells that lack EWS/FLI) with EF-2-RNAi
or control retroviruses. Following selection, cells were seeded in
soft agar to assess oncogenic transformation. We found that
A673 cells were severely restricted in their colony forming effi-
ciency by the EF-2-RNAi (Figure 2B). Loss of transformation
was dependent on the presence of EWS/FLI because 293EBNA
cells were unaffected by the EF-2-RNAi retrovirus (Figure 2B).
We next performed xenograft tumor formation assays. A673
Ewing’s sarcoma cells were engineered to express the lucifer-
ase protein and then infected with the EF-2-RNAi retrovirus (or
ERG-RNAi as a control). The control cells formed large tumors
in immunodeficient mice that could be observed with bio-
luminescent imaging (Figure 2C). EF-2-RNAi-infected cells
formed smaller tumors that were delayed in development as
compared to control cells (Figure 2C). The EF-2-RNAi tumors
that formed were ‘‘escapee’’ tumors that lost the RNAi effect
and regained EWS/FLI expression (Figure 2D). We did not note
a correlation between the level of reexpressed EWS/FLI protein
and tumor size in the escapee tumors. Taken together, these406data demonstrate that ongoing EWS/FLI expression is required
for the transformed phenotype of Ewing’s sarcoma cells.
To determine if the loss of transformation is due to knockdown
of EWS/FLI, or to ‘‘off-target’’ or other nonspecific effects, we
Figure 1. Targeting of EWS/FLI by retroviral RNAi
A: Schematic diagram of wild-type EWS, wild-type FLI, and the EWS/FLI fu-
sion transcripts. The locations of two Affymetrix probe sets that interrogate
EWS/FLI expression levels are indicated. The location of the EF-2-RNAi is
also indicated. A depiction of the EWS/FLI cDNA is provided.
B: Northern blot analysis of mRNA isolated from the Ewing’s sarcoma cell
lines A673, EWS502, SK-N-MC, and SK-ES-1 demonstrates that EWS/FLI is de-
tected by both the 30 FLI and 50 EWS probes. Wild-type EWS is detected by
both the 50 EWS and 30 EWS probes in all cell lines tested. Wild-type FLI is
only detectable in Jurkat T cells using the 50 FLI probe, but not in any of
the Ewing’s sarcoma cell lines. IVT indicates in vitro transcribed EWS/FLI tran-
script as a control. GAPDH is shown as a loading control.
C: Infection of A673 Ewing’s sarcoma cells with the EF-2-RNAi retrovirus results
in significantly decreased transcript levels as compared to control luc-RNAi
retrovirus, as determined by semiquantitative RT-PCR. GAPDH amplifies
equally from each sample.
D: Infection of A673 Ewing’s sarcoma cells with EF-2-RNAi retrovirus results in
a significant reduction in protein levels as compared to control luc-RNAi ret-
rovirus, as determined by Western blot using an anti-FLI antibody. Tubulin is
shown as a loading control.CANCER CELL MAY 2006
A R T I C L EFigure 2. RNAi against EWS/FLI blocks transformation
A: Growth assays (3T5 assays; Lessnick et al., 2002) for A673 Ewing’s sarcoma cells infected with either the EF-2-RNAi or the luc-RNAi control are shown.
B: Knockdown of EWS/FLI with the EF-2-RNAi blocks transformation in A673 Ewing’s sarcoma cells, but not in control 293 cells, as measured by soft agar assay.
Error bars indicate standard deviation.
C and D: Xenograft growth of A673 cells harboring the EF-2-RNAi is reduced as compared to those infected with ERG-RNAi retrovirus, as measured by biolu-
minescent imaging. However, the tumors that form have reexpressed EWS/FLI protein, as measured by Western blot with an anti-FLI antibody. The parental
A673 cell lines containing each RNAi retrovirus are shown as a comparison.performed ‘‘knockdown/rescue’’ experiments. A673 cells in-
fected with the EF-2-RNAi retrovirus were infected with a second
retrovirus containing an EWS/FLI cDNA. Because the cDNA
does not contain the 30 untranslated region of FLI (the region
to which the RNAi is directed), the EF-2-RNAi construct does
not affect this exogenous transcript (see Figure 1A). We found
that wild-type EWS/FLI completely rescued the transformed
phenotype, but the R2L2 DNA binding mutant could not (Fig-
ure 3A; Bailly et al., 1994).
We extended this analysis to include an inducible EWS/FLI
cDNA construct. We generated a clonal A673 cell line (clone
1-1, hereafter designated ‘‘Tet-A673’’) that contained the
FLAG-tagged EWS/FLI cDNA under the control of a tetracy-
cline-repressible promoter (Figure 3B). This clone had undetect-
able background levels of FLAG-tagged EWS/FLI when unin-
duced, produced detectible tagged EWS/FLI by 12 hr of
induction, and demonstrated maximal expression by 24 hr (Fig-
ure 3C). The amount of induced EWS/FLI was very similar to
endogenous wild-type levels (Figure 3B).
We repeated the knockdown/rescue experiments with Tet-
A673 cells containing either the ERG-RNAi control or EF-2-
RNAi retroviruses. Growth assays demonstrated that uninduced
Tet-A673 cells grew similarly with either retroviral construct,
supporting the results obtained in the noninducible cells (Fig-
ure 3D). Induction of EWS/FLI in the presence of the EF-2-
RNAi construct did not change the growth rate, as expected
(Figure 3D). Interestingly, when EWS/FLI expression was in-
duced in the presence of the control ERG-RNAi construct
(thus adding excess EWS/FLI protein in addition to endogenous
levels of the fusion), cell growth was significantly diminished,CANCER CELL MAY 2006demonstrating that supraphysiologic levels of EWS/FLI are a hin-
drance to cell growth (Figure 3D). The same effect was observed
in cells that did not contain the ERG-RNAi retrovirus, thus dem-
onstrating that this was not a synthetic effect related to the
retroviral construct (data not shown).
Soft agar assays demonstrated that inducible EWS/FLI res-
cued the loss of transformation caused by EF-2-RNAi (Fig-
ure 3E). The transformation observed in the uninduced cells
with the EF-2-RNAi is likely due to incomplete suppression of
the inducible construct in setting of 3 weeks of growth in soft
agar. We observed evidence of ‘‘leaky’’ expression in soft agar
previously (Lessnick et al., 2002). Furthermore, expression of
exogenous EWS/FLI in the presence of endogenous EWS/FLI
(i.e., supraphysiologic expression levels) prevented growth in
soft agar, again supporting the notion that EWS/FLI levels
must be tightly regulated for growth and transformation. These
data further support the hypothesis that ongoing EWS/FLI ex-
pression is required for the transformed phenotype of Ewing’s
sarcoma.
Transcriptional signature of EWS/FLI
Next, the gene expression profile of EWS/FLI as it relates to on-
cogenic transformation was determined. We, and others, have
previously shown that significant transcriptional consequences
are associated with changes in cell growth (e.g., Lessnick
et al., 2002; Zhang et al., 2004). Because A673 cells expressing
the EWS/FLI knockdown construct maintain normal growth
even though they are no longer transformed (Figures 2A and
3B), there should be minimal contribution of growth effects to
the transcriptional profile.407
A R T I C L EFigure 3. Rescue of EWS/FLI RNAi by an EWS/FLI
cDNA
A: A673 cells infected with EF-2-RNAi are in-
hibited for oncogenic transformation, as com-
pared to cells infected with the control ERG-
RNAi retrovirus, as measured by soft agar assays.
The transformation defect in A673 cells with EF-2-
RNAi is rescued following expression of wild-type
(wt) EWS/FLI cDNA, but not with an empty retro-
virus (no cDNA) or the EWS/FLI DNA binding mu-
tant R2L2. Error bars indicate standard deviation
of duplicate plates.
B: Induction of exogenous EWS/FLI in four differ-
ent inducible A673 clones in response to doxycy-
cline removal. Western blotting with an anti-FLAG
antibody only measures the inducible protein,
while blotting with anti-FLI measures both the
basal levels of EWS/FLI and the inducible fusion
levels. Clone 1-1 (subsequently called ‘‘Tet-
A673’’) induces similar levels of EWS/FLI as are in-
duced in tetEF cells, which have been previously
shown to express wild-type levels of EWS/FLI pro-
tein (Lessnick et al., 2002). Tubulin is shown as
a loading control.
C: Western blotting with an anti-FLAG antibody
demonstrates that inducible EWS/FLI protein is
detectable by 12 hr postinduction and reaches
maximal levels by 24 hr in Tet-A673 cells. A non-
specific background band is present at a slightly
higher molecular weight than the EWS/FLI band.
This band appears to correlate with either cell
density or time in culture, as it is present in the
later, but not in the earlier, time points. It is not
EWS/FLI as it is present in both induced and unin-
duced samples.
D: 3T5 growth analysis reveals that Tet-A673 cells
infected with the EF-2-RNAi retrovirus grow nearly
identically in the presence (+EWS/FLI) or absence
(2EWS/FLI) of induced EWS/FLI protein. Tet-A673
cells infected with a control ERG-RNAi retrovirus
grow well without induced EWS/FLI protein but
become severely growth restricted following in-
duction of additional EWS/FLI.
E: Soft agar assays demonstrate that Tet-A673
cells harboring the EF-2-RNAi construct form colo-
nies in soft agar following the induction of EWS/
FLI. Tet-A673 cells harboring the ERG-RNAi control
become restricted in their colony forming ability
following expression of inducible EWS/FLI protein.
Error bars indicate standard deviation of dupli-
cate plates.While we have demonstrated that off-target effects do not
mediate the loss of transformation observed in A673 cells in-
fected with the EF-2-RNAi retrovirus, off-target effects may still
be present (Jackson et al., 2003; Huppi et al., 2005). To control
for this, we identified a second EWS/FLI RNAi construct (desig-
nated EF-4-RNAi) that provides significant levels of EWS/FLI
knockdown and also disrupts oncogenic transformation (data
not shown). We reasoned that different RNAi constructs will
have distinct off-target effects, and identification of genes that
are altered similarly by both RNAi constructs would control for
these (Huppi et al., 2005).
A673 cells infected with either the EF-2-RNAi or EF-4-RNAi vi-
ruses were prepared, in duplicate with their associated controls,
and were subjected to microarray analysis. Because these cells
were grown in tissue culture for several weeks, these experi-
ments assessed the transcriptional changes that were stably408altered by the EWS/FLI fusion. We called these cells ‘‘stable
knockdown’’ cells.
To identify genes that were up- or downregulated in the pres-
ence of the EWS/FLI RNAi constructs, we sorted genes using
the signal-to-noise metric followed by permutation testing. We
found that EWS/FLI upregulated 320 genes and downregulated
1151 genes at the 95% confidence level (Figure 4A). The fact
that EWS/FLI downregulated so many more genes than it up-
regulated was counterintuitive since prior work (performed in
murine fibroblasts) suggested that EWS/FLI functions as a tran-
scriptional activator to mediate oncogenic transformation (Less-
nick et al., 1995; May et al., 1993b).
The ‘‘stable knockdown’’ results are likely to include bothdirect
and indirect EWS/FLI target genes. To determine which genes
are directly regulated by EWS/FLI, we attempted to perform
chromatin immunoprecipitation experiments. Unfortunately, weCANCER CELL MAY 2006
A R T I C L EFigure 4. Microarray analysis of A673 cells with
EWS/FLI RNAi
A: Oligonucleotide microarray data of A673 cells
with either EF-2-RNAi, EF-4-RNAi, or luc-RNAi con-
trol. Genes were rank ordered using the signal-
to-noise metric. The top 20 genes that either
increase with increased EWS/FLI (left side list) or
decrease with increased EWS/FLI (right side list)
are shown. ‘‘End. EWS/FLI’’ indicates the probe
set that is measuring endogenous EWS/FLI tran-
script levels. The color scale is shown (and is
used for all subsequent oligonucleotide expres-
sion data figures).
B: Microarray data of Tet-A673 cells harboring
the EF-2-RNAi retrovirus, and subsequently in-
duced to express the EWS/FLI cDNA for the time
periods shown. Columns labeled ‘‘72 unind.’’
and ‘‘24 unind.’’ indicate samples that were
grown for the specified times but were not in-
duced to express EWS/FLI. Genes were rank or-
dered using the Pearson correlation coefficient
on the basis of their similarity to reexpression of
EWS/FLI. The top 25 genes are listed.
C: Gene set enrichment analysis (GSEA) using
the 33 genes that were upregulated by EWS/FLI
in all four replicates from Figure 4A as the gene
set (see text for details). The rank-ordered list
was the list from Figure 4B. The high maximal nor-
malized enrichment score (NES) with the low p
value indicates highly significant similarity be-
tween the two data sets. The color plot represen-
tation of the genes is shown as well (lower portion
of panel).
D: GSEA using the 180 genes that were down-
regulated by EWS/FLI in all four replicates from
Figure 4A as the gene set. The rank-ordered list
was the list from Figure 4B. The very low minimal
NES with the very low p value again indicates
highly significant similarity between the two
data sets. The color plot representation of the
genes is shown as well (lower portion of panel).found unacceptably high levels of background immunoprecipita-
tion with commercially available EWS/FLI antibodies and were
unable to adequately complete these experiments.
As an alternate approach, we used an ‘‘inducible rescue’’ ex-
periment to enrich for genes that are likely to be direct EWS/FLI
targets. Endogenous EWS/FLI was knocked down with the
EF-2-RNAi retrovirus in Tet-A673 cells. The exogenous EWS/
FLI cDNA was then induced, and samples were collected at var-
ious times after induction, processed, and hybridized to oligonu-
cleotide microarrays.
Induction of the exogenous EWS/FLI transcript was moni-
tored with the 211825_s_at probe set (see Figure 1A). We iden-
tified 1326 genes with expression changes of at least 2.5-fold
and rank ordered these based on similarity of expression to
the induced exogenous EWS/FLI transcript using the Pearson
correlation coefficient as the distance metric (Figure 4B).
To compare the ‘‘stable knockdown’’ and ‘‘inducible rescue’’
experiments, we performed a modified gene set enrichmentCANCER CELL MAY 2006analysis (GSEA; Mootha et al., 2003). We first identified the
most reproducibly altered genes in the ‘‘stable knockdown’’
A673 cells described above. Using a 2.5-fold change cutoff
value, we identified 33 genes that were upregulated, and 180
genes that were downregulated by EWS/FLI in each of the
four replicates (see Figure 4A). We then compared these to
the 1326 rank-ordered genes from the ‘‘inducible rescue’’ cells.
If the two data sets are well correlated, we expect the EWS/
FLI-regulated genes in the stable knockdown experiment to
be enriched at the top of the rank-ordered list from the inducible
rescue experiment. This correlation was quantified using a nor-
malized running sum statistic called the normalized enrichment
score (NES). The maximal and minimal NES were determined.
The best possible NES is 100 (indicating perfect correlation),
and the worst possible NES is 2100 (indicating perfect inverse
correlation). An empiric p value was derived based on the num-
ber of times a maximal NES (or minimal NES) was obtained from
10,000 randomly chosen gene sets that was the same, or409
A R T I C L Egreater than, the experimentally determined value. Additional
details are presented in the Supplemental Data available with
this article online.
Comparison of the 33 EWS/FLI-upregulated genes to the in-
ducible rescue experiment yielded a maximal NES of 80.3 (p <
0.0001), indicating excellent correlation (Figure 4C). Compari-
son of the 180 EWS/FLI downregulated genes to the inducible
rescue experiment gave a minimal NES of 272.4 (p < 0.0001),
indicating a highly significant inverse correlation as one would
expect for downregulated genes (Figure 4D). Thus, the results
from the stable knockdown and inducible rescue experiments
are highly similar. We therefore conclude that the vast majority
of EWS/FLI-regulated genes are regulated in the same time
frame as EWS/FLI, suggesting that many of these are likely to
be direct EWS/FLI target genes.
To validate the microarray data using an alternate technique,
and to extend the results to other Ewing’s sarcoma cell lines,
we performed quantitative RT-PCR (qRT-PCR) analyses on
a random set of genes from Figure 4C. EWS/FLI was knocked
down in A673, SK-N-MC, and EWS-502 Ewing’s sarcoma cells
with the EF-2-RNAi retrovirus. Amplification of each gene was
compared in these cells to control cells expressing the luc-
RNAi control. We found that knockdown of EWS/FLI resulted in
similar decreases in each gene tested (Table S1). These results
confirm the initial microarray data and suggest that EWS/FLI reg-
ulates similar genes in other Ewing’s sarcoma cell lines as well.
Inspection of the data revealed that EWS/FLI upregulated
multiple genes related to neural differentiation, consistent with
the neural crest phenotype of Ewing’s sarcoma tumors. These
included NKX2.2, NPY1R, RET, EPHB3, DAB1, CDH12, and
CNTNAP2. These data support the previous assertion that
EWS/FLI itself induces the neural phenotype of Ewing’s sar-
coma, rather than the phenotype occurring as a consequence
of the tumor’s cell of origin (Teitell et al., 1999).
Identification of SSX family members (which are fused to SYT
in synovial sarcoma, another sarcoma of uncertain origin) sug-
gests the potential for common mechanisms of oncogenic
transformation across the fusion-associated solid tumors of ad-
olescents and young adults. The upregulation of GYG2, which
can nucleate the initial step of glycogen formation through auto-
glucosylation, suggests a molecular mechanism for the high
levels of glycogen observed in Ewing’s sarcoma (Mu et al.,
1997; Navas-Palacios et al., 1984). We also identified upregula-
tion of the SH2D1A gene, which encodes an SH2-domain-only
protein that is highly similar to EAT2, which has been previously
identified as an EWS/FLI target gene (Braun et al., 1995). EAT2
itself was not represented on the microarray used.
With respect to other previously identified EWS/FLI target
genes, TGFBR2 was repressed by EWS/FLI, as previously re-
ported (Hahm et al., 1999). MYC, ID2, MFNG, KRT15, UBE2C,
CYP2F1, and CDKN1C were not significantly altered (Arvand
et al., 1998; Bailly et al., 1994; Dauphinot et al., 2001; Fukuma
et al., 2003; May et al., 1997). Uridine phosphorylase (UPP1),
MMP3 (stromelysin 1), and PDGFC were downregulated, rather
than upregulated as previously reported (Braun et al., 1995; De-
neen et al., 2003; Zwerner and May, 2001). It should be noted
that many of these were identified in alternate models of EWS/
FLI expression (e.g., in NIH3T3 cells) rather than in Ewing’s
sarcoma itself.
To extend the analysis of previously reported EWS/FLI target
genes beyond those listed above, we compared the microarray410data we obtained in A673 Ewing’s sarcoma cells to publicly
available data generated in two alternate systems: human rhab-
domyosarcoma cells and primary human fibroblasts expressing
inducible EWS/FLI protein (RD-EF and tet-EF, respectively; Hu-
Lieskovan et al., 2005b; Lessnick et al., 2002). The list of EWS/
FLI-upregulated genes in each data set was compared to the
EWS/FLI-upregulated genes in both the stable knockdown
and the inducible rescue A673 cells using chi-square analysis.
We found small but highly significant overlaps between EWS/
FLI-regulated genes in both of these heterologous models and
the A673 systems (Table 1; see Supplemental Data for details
of the analysis and complete data sets). Thus, the A673 system
identified genes that were found in other EWS/FLI model
systems, supporting the validity of our model. The A673 model
also identified many genes that were not observed in these
heterologous systems, thus demonstrating the importance of
this model.
Comparison of EWS/FLI signatures to Ewing’s sarcoma
Ewing’s sarcoma is highly associated with the EWS/FLI onco-
protein. If the genes we identified are valid targets, they should
also be expressed in Ewing’s sarcoma, but not in other pediatric
tumors. To test this, we compared our data with publicly avail-
able microarray data on small round blue cell tumors of child-
hood (SRBCT; Khan et al., 2001), which included Ewing’s
sarcoma. The genes in the SRBCT data set were sorted to dis-
tinguish between Ewing’s sarcoma and the other tumors, using
the signal-to-noise metric as a distance measure (Lessnick
et al., 2002). The data sets were mapped to their UniGene iden-
tifiers to allow for comparisons between different microarray
platforms.
The stable knockdown and inducible rescue rank-ordered
lists were compared to the SRBCT list using the Spearman cor-
relation coefficient (Table 2). When used in this way, the Spear-
man coefficient quantifies the correlation of gene rank position
between data sets. An empiric p value was derived by repeat-
edly shuffling the rank order of one of the two data sets in
a pair, and determining the number of times that a correlation
coefficient was obtained that was higher than the experimentally
determined coefficient.
While both of our data sets showed significant similarity to the
human tumor data set, the inducible rescue data were more
closely correlated to the human tumor data than the stable
knockdown data, with a Spearman correlation coefficient of
0.43 versus 0.30, respectively (Table 2). These values were
highly statistically significant, with p values of <0.0001 for
each. Thus, the inducible rescue data more accurately identified
Table 1. Comparisons between A673 and other model systems
RD-EF Tet-EF
A673 stable knockdown 5.2 3 1024 1.5 3 1023
A673 inducible rescue 2 3 1028 1.4 3 1024
The gene expression data from the A673 ‘‘stable knockdown’’ (Figure 4A)
and ‘‘inducible rescue’’ (Figure 4B) were compared to the EWS/FLI-upregu-
lated genes identified in human rhabdomyosarcoma cells and primary hu-
man fibroblasts expressing inducible EWS/FLI (RD-EF and tet-EF cells, respec-
tively; Hu-Lieskovan et al., 2005b; Lessnick et al., 2002). The chi-square p
values for the overlapping gene sets are shown. A complete description
of the analysis and a full presentation of the data are provided in the
Supplemental Data.CANCER CELL MAY 2006
A R T I C L EEwing’s sarcoma-specific genes than the stable knockdown
data.
NKX2.2 is required for oncogenic transformation
Because loss of EWS/FLI results in loss of transformation, EWS/
FLI-regulated genes should include those required for Ewing’s
sarcoma development. Because prior data suggested that tran-
scriptional activation is critical to the function of EWS/FLI as an
oncoprotein, we focused our efforts on genes that were upregu-
lated by the fusion (Figure 4C). Using an RNAi approach to ana-
lyze the oncogenic role of candidate genes, we identified
NKX2.2 as a critical mediator of transformation mediated by
EWS/FLI (see below).
NKX2.2 is a homeobox containing-protein that has roles in
neuronal development but has never been implicated as having
a role in tumorigenesis (Briscoe et al., 1999). As shown in Table
S1, NKX2.2 transcript levels are regulated by EWS/FLI in multi-
ple Ewing’s sarcoma cell lines. NKX2.2 protein is also decreased
following knockdown of EWS/FLI in multiple Ewing’s sarcoma
cell lines (Figure 5A and data not shown). Thus, NKX2.2 is an
EWS/FLI target in multiple Ewing’s sarcoma cell lines, although
whether it is directly, or indirectly, regulated by EWS/FLI remains
to be determined.
We developed a retroviral NKX2.2 RNAi construct (designated
NKX-RNAi), and introduced it into A673 Ewing’s sarcoma cells.
This construct resulted in a 73% reduction of endogenous
NKX2.2 transcript levels (data not shown), which is similar to
the 84% reduction of NKX2.2 transcript levels following EWS/
FLI knockdown. NKX2.2 protein levels were similarly reduced
by NKX-RNAi (Figure 5B).
Knockdown of NKX2.2 had minimal effects on the growth rate
of A673 Ewing’s sarcoma cells (Figure 5C). There was no signifi-
cant increase in cell death observed (data not shown). This is sim-
ilar to what we observed with EWS/FLI knockdown (Figure 2A).
Introduction of NKX-RNAi into multiple Ewing’s sarcoma cells
resulted in a near complete loss of oncogenic transformation
both in soft agar assays (Figure 5D) and in a xenograft model
of Ewing’s sarcoma (Figure 5E). Transformation was rescued
when NKX2.2 was reexpressed using a cDNA that does not con-
tain the endogenous 30 UTR and so is unaffected by the RNAi
(Figure 5F). Taken together, these data show that NKX2.2 is nec-
essary for oncogenic transformation in Ewing’s sarcoma.
To determine if NKX2.2 is sufficient for transformation, we
knocked down EWS/FLI with the EF-2-RNAi retrovirus and
Table 2. Spearman correlation coefficient comparisons between ‘‘stable












The complete gene expression data from Figure 4A (stable knockdown)
and Figure 4B (inducible rescue) were rank ordered, as described in the
text, and compared to data from small round blue cell tumors (Khan
et al., 2001). The Spearman correlation coefficient is shown. The p value
was an empirically determined value based on 10,000 randomly generated
rank orders of the same data. The number of common genes indicates how
many genes were present in each pairwise comparison.CANCER CELL MAY 2006reintroduced NKX2.2 expression from the cDNA-containing ret-
roviral vector. We found that NKX2.2 could not rescue the loss of
transformation resulting from EWS/FLI knockdown (Figure 5G).
We also found that NKX2.2 did not induce oncogenic transfor-
mation in NIH3T3 murine fibroblasts (data not shown). Thus,
although NKX2.2 is necessary for oncogenic transformation in
Ewing’s sarcoma, it is not sufficient.
We reasoned that, if NKX2.2 were a critical EWS/FLI target
gene, then it should be expressed in patient-derived primary
Ewing’s sarcoma tumor samples as well. We performed re-
verse-transcriptase polymerase chain reaction (RT-PCR) for
NKX2.2 in four Ewing’s sarcoma tumor samples. NKX2.2 was
expressed in each of the tumor samples, but not in normal hu-
man fibroblasts (Figure 6A). We then analyzed the expression
pattern of NKX2.2 in a recently published microarray data set
containing 181 sarcoma tumor samples, including 20 Ewing’s
sarcomas (Baird et al., 2005). NKX2.2 was expressed in most
(18 of 20) Ewing’s sarcoma samples, but was expressed in
only 7 of 161 of the other tumors (Figure 6B). In this data set,
then, NKX2.2 is an excellent marker of Ewing’s sarcoma, with
a sensitivity of 90% and a specificity of 96%. These data support
the assertion that NKX2.2 is a critical EWS/FLI target gene re-
quired for oncogenic transformation in Ewing’s sarcoma and
also suggest that NKX2.2 may serve as a diagnostic marker
for this disease.
Discussion
The identification of EWS/FLI over a decade ago suggested that
more specific and less toxic therapies for Ewing’s sarcoma
would be feasible (Delattre et al., 1992). Unfortunately, this
hope has not been realized. One particular difficulty has been
the uncertainty regarding Ewing’s sarcoma’s cell of origin and
the lack of an appropriate cell type in which to study the fusion
protein. We circumvented this difficulty by analyzing EWS/FLI in
patient-derived Ewing’s sarcoma cells using a loss-of-function
approach with retroviral-mediated RNAi.
We found that ongoing expression of EWS/FLI is absolutely
required for tumorigenesis in Ewing’s sarcoma. Loss of EWS/
FLI resulted in loss of transformation, while reexpression of
EWS/FLI rescued this phenotype. In contrast to prior studies
conducted in NIH3T3 cells (Jaishankar et al., 1999; Welford
et al., 2001), we found that the DNA binding function of EWS/
FLI was required for its oncogenic function. In addition, our re-
sults demonstrate that EWS/FLI does not function via a ‘‘hit
and run’’ mechanism whereby it initiates the transformation pro-
cess and then is no longer required. This finding also demon-
strates that EWS/FLI expression does not result in ‘‘oncogene
addiction,’’ whereby the brief inactivation of an oncogene is suf-
ficient to result in sustained loss of the tumorigenic phenotype
(Jain et al., 2002). Because EWS/FLI is required for the onco-
genic phenotype of Ewing’s sarcoma, targeting the fusion may
be a useful therapeutic modality for this disease, which is sup-
ported by a recent publication (Hu-Lieskovan et al., 2005a).
Interestingly, EWS/FLI expression is not required for the
growth of A673 Ewing’s sarcoma cells in tissue culture. In these
cells, at least, the oncogenic function of EWS/FLI has been dis-
sociated from other potential growth effects. We have noticed
that growth is adversely effected by loss of EWS/FLI in some
Ewing’s sarcoma cell lines (data not shown). The differences
in cellular background that determine cellular response to loss411
A R T I C L EFigure 5. NKX2.2 is a critical EWS/FLI target gene required for oncogenesis
A: Western blot of A673 cells harboring the EF-2-RNAi retrovirus, or the luc-RNAi control, demonstrates that NKX2.2 protein levels are significantly decreased
following knockdown of EWS/FLI. Tubulin is shown as a loading control.
B: Western blot analysis of A673 cells demonstrates that the NKX-RNAi retrovirus efficiently knocks down endogenous NKX2.2 protein. Tubulin is shown as a load-
ing control.
C: Growth analysis using a 3T5 assay (Lessnick et al., 2002) demonstrates that A673 cells harboring the NKX-RNAi retrovirus grow nearly as well as cells contain-
ing the luc-RNAi control virus.
D: Soft agar assays using A673, SK-N-MC, and EWS502 Ewing’s sarcoma cells demonstrate that knockdown of NKX2.2 with the NKX-RNAi retrovirus results in
a near complete loss of transformation as compared to the control luc-RNAi containing cells. A graphical representation of colony formation is shown. Error
bars indicate standard deviation of duplicate plates.
E: Murine xenograft experiments using TC71 Ewing’s sarcoma cells expressing a luc-neo fusion protein that were subsequently infected with either the ERG-
RNAi or NKX-RNAi retroviruses demonstrate that NKX2.2 is required for tumor formation in immunodeficient mice. Bioluminescent imaging data is shown in
the left panel. Tumor photon emission is shown in the middle panel, and tumor size is shown in the right panel, where numbers indicate separate tumor injection
sites. p values from Student’s t tests are also shown.
F: Soft agar assays of A673 and SK-N-MC cells demonstrate that transformation is rescued by reexpression of NKX2.2 using a cDNA that does not contain the 30
UTR (the region to which NKX-RNAi is directed). Error bars indicate standard deviation of duplicate plates.
G: A673 cells infected with the EF-2-RNAi retrovirus were subsequently infected with either control empty retroviruses (labeled ‘‘none’’), retrovirus expressing
EWS/FLI, or retrovirus expressing NKX2.2. Only expression of EWS/FLI rescued the loss of transformation induced by the EF-2-RNAi retrovirus. Error bars indicate
standard deviation.412 CANCER CELL MAY 2006
A R T I C L EFigure 6. NKX2.2 is expressed in Ewing’s sarcoma
tumor samples
A: RT-PCR analysis demonstrates that NKX2.2
transcript is expressed in four different patient-
derived Ewing’s sarcoma tumor samples, but
not in human fibroblasts. GAPDH was used as
an amplification control.
B: Graphical representation of NKX2.2 expression
levels across 181 sarcoma tumor samples, includ-
ing 20 cases of Ewing’s sarcoma. Tumor types are
indicated. Primary data from Baird et al. (2005).of EWS/FLI are unknown. It is fortunate that A673 cells maintain
a normal growth rate following EWS/FLI knockdown, because
that has provided the unique opportunity to isolate and analyze
the transformation effects of EWS/FLI without the confounding
effects of growth arrest or cell death.
One surprising finding in the microarray data was that EWS/
FLI downregulates three to four times as many genes as it up-
regulates. This was unanticipated because most prior studies
suggested that EWS/FLI functions as a transcriptional activator
(e.g., Lessnick et al., 1995; May et al., 1993b). This observation
was also noted in a recent publication that used transfected
siRNA against EWS/FLI (Prieur et al., 2004). There are at least
three models to account for this observation. First, EWS/FLI
may contain a transcriptional repressive domain that has not
yet been identified. This domain may function to repress some
genes, while the transcriptional activation domain may stimulate
the expression of others. Second, EWS/FLI may function as
a dominant-negative at some promoters by competing with
other ETS family members for DNA binding, and thus preventing
these ETS factors from stimulating transcription. Third, EWS/FLI
may upregulate a transcriptional repressor. In this case, tran-
scriptional repression would be an indirect effect. Future work
will be required to distinguish between these models.
EWS/FLI is known to function as an aberrant transcription fac-
tor, but the mechanisms by which EWS/FLI-regulated genes
mediate Ewing’s sarcoma development are largely unknown. In-
deed, there are multiple possibilities. For example, EWS/FLICANCER CELL MAY 2006may upregulate a ‘‘strong’’ oncogene that would be both neces-
sary and sufficient for transformation. Strong oncogenes such
as MYC and/or CCND1 (encoding cyclin D1) appear to be up-
regulated by EWS/FLI in some models (Dauphinot et al., 2001;
Hu-Lieskovan et al., 2005b; Lessnick et al., 2002), but not in
others (Arvand et al., 2001; Prieur et al., 2004; this report). Alter-
nately, EWS/FLI may upregulate multiple ‘‘weak’’ oncogenes,
each of which contributes partially to transformation. These
models are not mutually exclusive. Loss of any one of these
would then have a small quantitative effect on transformation.
This appears to be the case in NIH3T3 cells, where EWS/FLI up-
regulates genes such asMFNG, EAT2, andUPP1, each of which
appear to contribute partially to oncogenic transformation (De-
neen et al., 2003; May et al., 1997; Thompson et al., 1996).
The observation that NKX2.2 is necessary, but not sufficient,
for transformation suggests that, in Ewing’s sarcoma cells,
EWS/FLI regulates multiple nonredundant cooperating genes.
Based on this model, we hypothesize that other EWS/FLI-regu-
lated genes will also participate in this process. Another possi-
bility to be explored is that some of the downregulated target
genes may function as tumor suppressors to prevent oncogenic
transformation.
In addition to its role in oncogenic transformation described in
this report, NKX2.2 is also interesting because of its previously
defined role in neural development. NKX2.2 is a member of
the NK2 family of homeobox genes (Kim and Nirenberg, 1989).
NKX2.2 is expressed in the developing forebrain and spinal413
A R T I C L Ecord and is thought to underlie neuronal development, pattern-
ing, and fate specification of neurons and oligodendrocytes
(McMahon, 2000; Price et al., 1992; Qi et al., 2001). NKX2.2
has not been previously implicated in cancer development.
While the cell of origin of Ewing’s sarcoma is unknown, one pre-
vailing theory is that it is derived from the neural crest (e.g., Cav-
enzzana et al., 1987; Collini et al., 2003; Staege et al., 2004).
Importantly, however, the neural crest phenotype may be a
consequence of EWS/FLI expression, rather than being related
to the cell of origin of the tumor (Hu-Lieskovan et al., 2005b; Tei-
tell et al., 1999; Thompson et al., 1999). As an EWS/FLI target
gene, NKX2.2 may thus contribute to the neural characteristics
of the tumor. Future work will be directed toward understanding
the mechanism by which NKX2.2 participates in oncogenesis of
Ewing’s sarcoma, and whether it plays a role in the neural phe-
notype as well.
Based on the work presented in this report, NKX2.2 may be
either a direct or an indirect EWS/FLI target gene. NKX2.2 ex-
pression is tightly correlated with EWS/FLI expression in the
inducible rescue data set, suggesting thatNKX2.2 is a direct tar-
get. We attempted to perform luciferase assays with theNKX2.2
promoter in human embryonic kidney cells (293EBNA) but were
unable to document direct regulation (data not shown). While
one interpretation of this result is that NKX2.2 is not a direct
EWS/FLI target gene, alternate explanations include the follow-
ing: (1) the EWS/FLI-response element was not in our construct;
(2) a required cofactor was not present in the heterologous cells;
or (3) a repressor was present in the heterologous cells that
prevented EWS/FLI from demonstrating transcriptional activa-
tion in this setting. Additional work will be required to understand
the detailed mechanism of NKX2.2 gene regulation in Ewing’s
sarcoma.
The identification of NKX2.2 as a critical EWS/FLI target gene
has important diagnostic and therapeutic implications. First, the
demonstration that NKX2.2 is not only expressed in Ewing’s sar-
coma cell lines, but is also expressed in primary patient-derived
tumor samples, suggests that it may serve as a diagnostic
marker for this tumor. This is important because the diagnosis
of Ewing’s sarcoma is primarily based on the histologic appear-
ance of the tumor and an appropriate immunohistochemical
staining pattern. The main immunohistochemical marker for Ew-
ing’s sarcoma is CD99 (also called MIC2; Ambros et al., 1991).
CD99 expression is not specific to Ewing’s sarcoma and can
also be found on lymphocytes and other hematopoietic cells,
endothelial cells, and other tumor types (Choi et al., 2001; Dwor-
zak et al., 1994; Matias-Guiu et al., 1998; Schenkel et al., 2002).
While EWS/FLI and other translocations are thought to be highly
specific for Ewing’s sarcoma, molecular tests for these translo-
cations are not universally applied to biopsy specimens. A new
marker would increase the diagnostic specificity for this tumor.
NKX2.2 may also serve as a therapeutic target for Ewing’s
sarcoma. We have shown that loss of NKX2.2 expression via
RNAi results in a loss of oncogenic transformation. Therapeutic
approaches directed against NKX2.2 may have clinical value for
patients with this disease. With some important exceptions,
transcription factors have been difficult to therapeutically target.
It seems likely that NKX2.2 will regulate downstream genes that
are involved in the oncogenesis of Ewing’s sarcoma. Identifica-
tion and analysis of these gene products may identify more clin-
ically tractable targets. Future work will be directed toward this
goal as well.414Experimental procedures
Constructs and retroviruses
The RNAi retroviral vector pSRP contains an H1 promoter for expression of
shRNAs, and a puromycin resistant marker. Oligonucleotide sequences
that were cloned downstream of the H1 promoter are provided in the Supple-
mental Data. For some experiments, the puromycin resistance cassette was
replaced with a hygromycin resistance cassette. The NKX-RNAi retrovirus
used the pMKO.1puro vector (Masutomi et al., 2003). NKX-RNAi oligonucle-
otide sequences are provided in the Supplemental Data.
A FLAG epitope-tagged EWS/FLI cDNA (type 4 breakpoint; May et al.,
1993a), or the R2L2 mutant (Bailly et al., 1994), was cloned into the
pMSCV-puro retroviral vector (Clontech). A full-length NKX2.2 cDNA was
cloned into the retroviral expression vector pQCXIN (Clontech). The inducible
EWS/FLI construct, retroviral production, and retroviral infection were previ-
ously described (Lessnick et al., 2002).
Cell culture
Ewing’s sarcoma cell lines were grown as described (Lessnick et al., 2002).
Following retroviral infection, polyclonal cell populations were prepared by
growth in the appropriate selective media. Soft agar assays were performed
as described (Lessnick et al., 2002).
Tet-A673 cells were generated by infection with pREV-TETOFF (Clontech)
and selection with G418. A single clone was then infected with FLAG-EWS/
FLI-pREV-TRE and selected with hygromycin in the presence of 1 mg/ml doxy-
cycline and G418 (Lessnick et al., 2002). Individual clones were tested for
induction of FLAG-EWS/FLI as previously described (Lessnick et al., 2002).
Xenograft imaging
A673 or TC71 cells were infected with pMMP-LucNeo and selected with
G418 (Rubin et al., 2003). They were then infected with either EF-2-RNAi,
NKX-RNAi, or ERG-RNAi retroviruses and selected with puromycin. Follow-
ing selection, 1 3 106 cells were injected into the flanks of nude mice. Mice
were imaged weekly using a Xenogen IVIS 100 imaging system, per the
manufacturer’s directions. Animal experiments were performed following
approval from the University of Utah Institutional Animal Care and Use
Committee.
Northern blot analysis
Positive control EWS/FLI RNA was prepared using an in vitro transcription re-
action. One microgram of mRNA (Ewing’s cells), 1 mg of total RNA (Jurkatt
cells), or 0.01 mg of in vitro transcribed EWS/FLI RNA was used. Probes for
EWS were prepared using PCR to amplify coding bases 1 to 793 (for 50
EWS) or coding bases 802 to 1607 (for 30 EWS). The 50 FLI probe was pre-
pared using PCR to amplify coding bases 44 to 604. The 30 FLI probe was
a 475 bp PvuII-HindIII fragment derived from the EWS/FLI cDNA.
RT-PCR
Total RNA from the indicated sources was amplified and detected using
SYBR green fluorescence for quantitative analysis. For nonquantitative anal-
ysis, total RNA was amplified for 35 cycles, and the PCR products were sub-
jected to agarose gel electrophoresis. Primer sequences are available on
request. Deidentified patient samples were obtained through an approved
University of Utah Institutional Review Board Protocol.
Immunodetection
The following antibodies were used for immunodetection: M2-anti-FLAG
(Sigma), anti-FLI-1 (BD PharMingen 554266), anti-a-tubulin (Santa Cruz sc-
5286), anti-NKX2.2 (Santa Cruz sc-15015).
Microarray analysis
A complete description of the microarray analysis is provided in the Supple-
mental Data. The complete set of microarray data is available online at http://
www.ncbi.nlm.nih.gov/projects/geo/ (accession number GSE4565).
Supplemental data
The Supplemental Data can be found with this article online at http://www.
cancercell.org/cgi/content/full/9/5/405/DC1/.CANCER CELL MAY 2006
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